Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a pivotal peptide in the global pharmaceutical and healthcare industries. Approved by major regulatory bodies like the FDA and EMA, it is widely recognized for its dual efficacy in treating type 2 diabetes mellitus (T2DM) and chronic weight management, addressing two interconnected global health challenges.

Derived from the naturally occurring GLP-1 hormone, liraglutide works by enhancing insulin secretion, suppressing glucagon release, and slowing gastric emptying—mechanisms that effectively regulate blood glucose levels in T2DM patients. For weight management, it curbs appetite and reduces energy intake, making it a key option for individuals with obesity or overweight conditions linked to comorbidities.

In recent years, the market demand for liraglutide has surged. Its long-acting formulation (administered once daily) improves patient compliance, a critical factor driving its adoption in clinical settings. Beyond T2DM and weight management, ongoing clinical trials are exploring its potential in treating non-alcoholic fatty liver disease (NAFLD) and heart failure, expanding its application scope and market prospects.

As the global focus on metabolic health intensifies, liraglutide remains a core product in the portfolios of leading pharmaceutical companies. Its role in advancing personalized medicine and chronic disease prevention underscores its significance as a high-value peptide in the modern healthcare landscape.